In recognition of the imbalance between the dwindling antibacterial drug pipeline and the significant clinical need for new antibiotics to treat antibacterial-resistant infections, IDSA has launched a new advocacy campaign called the
10 x '20 initiative—an effort to mobilize key leaders and resources around a specific goal—to create an antibacterial research and development enterprise powerful enough to produce 10 new antibiotics by the year 2020. IDSA’s statement describing the 10 x '20 initiative is available in the April 15 issue of Clinical Infectious Diseases.
Prior generations gave us the gift of antibiotics. Today, our global community has a moral obligation to ensure this global treasure is available for our children and future generations. For that reason, earlier this month, I reached out to U.S. Health and Human Services Secretary Kathleen Sebelius and other government leaders, including Anthony Fauci, MD, director of the National Institute for Allergy and Infectious Diseases (NIAID), and Peggy Hamburg, MD, commissioner of the U.S. Food and Drug Administration (FDA), asking that they commit to the 10 x '20 goal and work with IDSA to tackle this major public health problem.
To educate policymakers about the need for new drugs and the 10 x '20 initiative and the problem of antibiotic resistance in general, IDSA has launched a new monthly e-newsletter targeting Congress. The Antibiotic Resistance Policy Update focuses on three key areas:
- antibiotic research and development and the need for government action to achieve the
10 x '20 goal;
- antibiotic resistance in health care facilities and communities and the need to enact the Strategies to Address Antimicrobial Resistance Act (H.R. 2400), which will strengthen federal antimicrobial resistance surveillance, prevention and control and research efforts;
- antibiotic use and resistance on the farm and the need to enact the Preservation of Antibiotics for Medical Treatment Act (H.R. 1549/S.619) in combination with the FDA’s recently announced public health approach for using antibiotics in food animals.
You may view the Antibiotic Resistance Policy Update e-news online.
Finally, IDSA is working to put a human face on this major public health problem and to demonstrate that antibiotic resistance has enormous costs in terms of lives lost and dollars spent in every U.S. state and around the world. IDSA members can help in important ways by sharing patient stories with us, using IDSA’s advocacy center to contact members of Congress, and by promoting the uptake of IDSA’s antimicrobial stewardship guidelines in your community.
Next Article >